Skip to main content

IAVI S001

Phase:
I
Status:
Ongoing
Strategies:
Replicating Vector
Candidates:
SeV-G(NP)
Countries:
United Kingdom;Kenya;Rwanda
Volunteers:
64
Partners:
DNAVEC, PSF-Kigali, (Rwanda), Kenyatta National Hospital-KAVI (Kenya), St. Stephen’s Centre, London (UK)

A Phase I double-blind, randomized, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly in prime-boost regimens in HIV-uninfected, healthy adult volunteers.